ANAFERON Affinity-Purified Antibodies to Human Interferon Gamma 3mg Orodispersible Tablet 20's
RXDRUG-BR-1196
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Prophylaxis and treatment of influenza for children (6 months-14 years).
Dosage/Direction for Use
Oral route.
Affinity-purified antibodies to human interferon gamma (Anaferon) should be administered by children from 6 months to 14 years of age.
One tablet per intake (the tablet should be held in the mouth until it is completely dissolved, not during the meal).
When indicated to younger children (6 months - 3 years old) the tablet is recommended to be dissolved in a small volume (a tablespoonful) of drinking water at room temperature.
Influenza: On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2, one tablet is taken three times daily until complete recovery.
If no improvement occurs by the third day of treatment of acute respiratory virus infections and influenza, a doctor should be consulted.
Throughout the epidemic season for prophylaxis purposes the drug is administered 1 tablet daily for 1-3 months.
If necessary Affinity-purified antibodies to human interferon gamma (Anaferon) can be coadministered with other antiviral and symptomatic drugs.
Affinity-purified antibodies to human interferon gamma (Anaferon) is not recommended for use in children below age of 6 months due to a lack of data on safety and efficacy.
Affinity-purified antibodies to human interferon gamma (Anaferon) should be administered by children from 6 months to 14 years of age.
One tablet per intake (the tablet should be held in the mouth until it is completely dissolved, not during the meal).
When indicated to younger children (6 months - 3 years old) the tablet is recommended to be dissolved in a small volume (a tablespoonful) of drinking water at room temperature.
Influenza: On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2, one tablet is taken three times daily until complete recovery.
If no improvement occurs by the third day of treatment of acute respiratory virus infections and influenza, a doctor should be consulted.
Throughout the epidemic season for prophylaxis purposes the drug is administered 1 tablet daily for 1-3 months.
If necessary Affinity-purified antibodies to human interferon gamma (Anaferon) can be coadministered with other antiviral and symptomatic drugs.
Affinity-purified antibodies to human interferon gamma (Anaferon) is not recommended for use in children below age of 6 months due to a lack of data on safety and efficacy.
Overdosage
Overdose of this product can cause dyspeptic disorders due to excessive intake of excipients.
Treatment should be symptomatic.
Treatment should be symptomatic.
Contraindications
Individual hypersensitivity to components of the medicine.
Special Precautions
Medicine contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Effects on ability to drive and use machines: Affinity-purified antibodies to human interferon gamma (Anaferon) has no or negligible influence on the ability to drive and use machines.
Effects on ability to drive and use machines: Affinity-purified antibodies to human interferon gamma (Anaferon) has no or negligible influence on the ability to drive and use machines.
Use In Pregnancy & Lactation
Use in Pregnancy: There are no or limited amount of data from the use of Affinity-purified antibodies to human interferon gamma (Anaferon) in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive/foetal toxicity. As a precautionary measure, it is preferable to avoid the use of Affinity-purified antibodies to human interferon gamma (Anaferon) during pregnancy.
Use in Lactation: It is unknown whether Affinity-purified antibodies to human interferon gamma (Anaferon) and/or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Affinity purified antibodies to human interferon gamma (Anaferon) should not be used during breast-feeding.
Use in Lactation: It is unknown whether Affinity-purified antibodies to human interferon gamma (Anaferon) and/or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Affinity purified antibodies to human interferon gamma (Anaferon) should not be used during breast-feeding.
Adverse Reactions
Allergic reactions and individual hypersensitivity to components of the medicine are possible.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacotherapeutic Group: Antivirals. ATC Code: JO5AX.
Pharmacology: Pharmacodynamics: The medicine exerts antiviral effects upon prophylactic and therapeutic administration. Effectiveness is established experimentally and clinically towards influenza viruses, parainfluenza viruses, herpes simplex virus of type 1 and 2 (labial herpes, genital herpes), other herpes virus diseases (varicella, infectious mononucleosis), enterovirus, tick-borne encephalitis virus, rotavirus, coronavirus, calicivirus, adenovirus, respiratory syncytial virus. The drug reduces the concentration of virus in the affected tissues, influences on the system of endogenous interferons and related cytokines, induces the production of endogenous "early" interferons (IFN a/(3) and interferon gamma (IFN y).
The drug stimulates humoral and cell-mediated immune responses. Affinity-purified antibodies to human interferon gamma (Anaferon) increases antibody production (including secretory IgA), activates the functions of T-effectors and T-helpers (Th) and normalizes their ratio. The drug increases the functional reserves of Th and other cells involved in the immune response. The drug induces combined Th1 and Th2-type immune response through enhancing the production of Thl (IFN y, IL-2) and Th2 (IL-4, 10) cytokines, normalizes (modulates) the Thl/Th2 activity balance. The drug increases the functional activity of phagocytes and natural killer cells (NK cells).
Pharmacokinetics: The sensitivity of contemporary physicochemical methods (gas-liquid chromatography, high performance liquid chromatography and mass spectrometry) does not allow assessing the content of active components of the drug in biological fluids, organs and tissues, that makes technically impossible to investigate the pharmacokinetic properties of Affinity-purified antibodies to human interferon gamma (Anaferon).
Pharmacology: Pharmacodynamics: The medicine exerts antiviral effects upon prophylactic and therapeutic administration. Effectiveness is established experimentally and clinically towards influenza viruses, parainfluenza viruses, herpes simplex virus of type 1 and 2 (labial herpes, genital herpes), other herpes virus diseases (varicella, infectious mononucleosis), enterovirus, tick-borne encephalitis virus, rotavirus, coronavirus, calicivirus, adenovirus, respiratory syncytial virus. The drug reduces the concentration of virus in the affected tissues, influences on the system of endogenous interferons and related cytokines, induces the production of endogenous "early" interferons (IFN a/(3) and interferon gamma (IFN y).
The drug stimulates humoral and cell-mediated immune responses. Affinity-purified antibodies to human interferon gamma (Anaferon) increases antibody production (including secretory IgA), activates the functions of T-effectors and T-helpers (Th) and normalizes their ratio. The drug increases the functional reserves of Th and other cells involved in the immune response. The drug induces combined Th1 and Th2-type immune response through enhancing the production of Thl (IFN y, IL-2) and Th2 (IL-4, 10) cytokines, normalizes (modulates) the Thl/Th2 activity balance. The drug increases the functional activity of phagocytes and natural killer cells (NK cells).
Pharmacokinetics: The sensitivity of contemporary physicochemical methods (gas-liquid chromatography, high performance liquid chromatography and mass spectrometry) does not allow assessing the content of active components of the drug in biological fluids, organs and tissues, that makes technically impossible to investigate the pharmacokinetic properties of Affinity-purified antibodies to human interferon gamma (Anaferon).
MedsGo Class
Vaccines, Antisera & Immunologicals
Features
Brand
ANAFERON
Full Details
Dosage Strength
3 mg
Drug Ingredients
- Affinity-Purified Antibodies to Human Interferon Gamma
Drug Packaging
Orodispersible Tablet 20's
Generic Name
Affinity-Purified Antibodies to Human Interferon Gamma
Dosage Form
Orodispersible Tablet
Registration Number
BR-1196
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply